|
Taking
care of bio-security business
by David Filmore
PDF
version (260 KB PDF)
Although approved vaccines already exist for smallpox and anthrax, their use has
been curtailed by safety concerns and, in the case of anthrax, complicated dosing
schedules. Moreover, there are no vaccines and very limited treatment options
for other conditions like pneumonic plague, botulism, tularemia, and viral hemorrhagic
fevers. Biotech companies are responding to this need, encouraged by Congresss
plan to spend $5.6 billion over the next 10 years to stockpile countermeasures.
Building
a framework
by Bill Ladd
PDF
version (136 KB PDF)
HTS automation has created a data bottleneck for scientists: The ability to generate
data exceeds the ability to convert it into useful information. Advances in areas
such as combinatorial chemical synthesis have resulted in screening libraries
of compounds measured in the millions. All of this drives the need for high-throughput
analytics, and has spawned a range of new analytical tools and new ways to deliver
HTS results to chemists and scientists.
|
|